Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis

Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa

(2016) Joel W. Hay et al.   JOURNAL OF MEDICAL ECONOMICS

Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study

(2014) O. Stasyshyn et al.   HAEMOPHILIA

Development of DEMQOL-U and DEMQOL-PROXY-U: generation of preference-based indices from DEMQOL and DEMQOL-PROXY for use in economic evaluation

(2014) B Mulhern et al.   HEALTH TECHNOLOGY ASSESSMENT

The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease

(2014) Séverine Henrard et al.   Orphanet Journal of Rare Diseases

Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study

(2013) Hartmut Pollmann et al.   ANNALS OF HEMATOLOGY

Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s

(2013) K. Fischer et al.   BLOOD

Physical and mental quality of life in adult patients with haemophilia in Belgium: the impact of financial issues

(2013) A. M. Carvalhosa et al.   HAEMOPHILIA

Long-term outcome of multiple joint procedures in haemophilia

(2013) P. de Kleijn et al.   HAEMOPHILIA

Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study

(2013) A. Gringeri et al.   HAEMOPHILIA

Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment

(2013) A. Farrugia et al.   HAEMOPHILIA

Responsiveness of Health State Utility Values in Knee Osteoarthritis

(2013) E. M. Davis et al.   JOURNAL OF RHEUMATOLOGY

US Valuation of the SF-6D

(2013) Benjamin M. Craig et al.   MEDICAL DECISION MAKING

Economic evaluation in short bowel syndrome (SBS): an algorithm to estimate utility scores for a patient-reported SBS-specific quality of life scale (SBS-QoL™)

(2013) Andrew Lloyd et al.   QUALITY OF LIFE RESEARCH

What is the role of prophylaxis in the improvement of health-related quality of life of patients with hemophilia?

(2013) D. Buchbinder et al.   Hematology-American Society of Hematology Education Program

Responsiveness of EQ-5D and SF-6D in patients with early arthritis: results from the ESPOIR cohort

(2012) Cécile Gaujoux-Viala et al.   ANNALS OF THE RHEUMATIC DISEASES

Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities

(2012) Christine Blome et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy

(2012) K. Lindvall et al.   HAEMOPHILIA

Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much?

(2012) A. H. Miners   HAEMOPHILIA

Treatment patterns, health-related quality of life and adherence to prophylaxis among haemophilia A patients in the United States

(2012) N. DUNCAN et al.   HAEMOPHILIA

A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries

(2012) D. Noone et al.   HAEMOPHILIA

Health technology assessment and haemophilia

(2012) A. FARRUGIA et al.   HAEMOPHILIA

Quality of life in haemophilia A: Hemophilia Utilization Group Study Va (HUGS-Va)

(2012) J.-L. POON et al.   HAEMOPHILIA

Cross-cultural adaptation and linguistic validation of age-group-specific haemophilia patient-reported outcome (PRO) instruments for patients and parents

(2012) S. von Mackensen et al.   HAEMOPHILIA

Standardization and Regulatory Guidelines May Inhibit Science and Reduce the Usefulness of Analyses Based on the Application of Preference-Based Measures for Policy Decisions

(2012) David Feeny   MEDICAL DECISION MAKING

Canadian Valuation of EQ-5D Health States: Preliminary Value Set and Considerations for Future Valuation Studies

(2012) Nick Bansback et al.   PLoS One

Evaluation of content on EQ-5D as compared to disease-specific utility measures

(2012) Fang-Ju Lin et al.   QUALITY OF LIFE RESEARCH

Effect of Acute Bleeding on Daily Quality of Life Assessments in Patients with Congenital Hemophilia with Inhibitors and Their Families: Observations from the Dosing Observational Study in Hemophilia

(2012) Ellis J. Neufeld et al.   VALUE IN HEALTH

Condition-Specific Preference-Based Measures: Benefit or Burden?

(2012) Matthijs M. Versteegh et al.   VALUE IN HEALTH

Methods and issues associated with the use of quality-adjusted life-years

(2012) Dennis A Revicki et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Autism spectrum disorders: a review of measures for clinical, health services and cost–effectiveness applications

(2012) Nalin Payakachat et al.   Expert Review of Pharmacoeconomics & Outcomes Research

A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A

(2011) K. Fischer et al.   HAEMATOLOGICA

Factor VIII inhibitors: a 50-year perspective

(2011) D. GREEN   HAEMOPHILIA

The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities

(2011) Paulos Teckle et al.   Health and Quality of Life Outcomes

Systematic Review and Empirical Comparison of Contemporaneous EQ-5D and SF-6D Group Mean Scores

(2011) David G. T. Whitehurst et al.   MEDICAL DECISION MAKING

Eliciting Benefit–Risk Preferences and Probability-Weighted Utility Using Choice-Format Conjoint Analysis

(2011) George Van Houtven et al.   MEDICAL DECISION MAKING

Challenges in Health State Valuation in Paediatric Economic Evaluation

(2011) Wendy J. Ungar   PHARMACOECONOMICS

Health Utility Elicitation

(2011) Lisa A. Prosser et al.   PHARMACOECONOMICS

EQ-5D for the Assessment of Health-Related Quality of Life and Resource Allocation in Children: A Systematic Methodological Review

(2011) J. Noyes et al.   VALUE IN HEALTH

Burden of Disease Resulting from Hemophilia in the U.S.

(2010) Azfar-e-Alam Siddiqi et al.   AMERICAN JOURNAL OF PREVENTIVE MEDICINE

QALY weights for neurosensory impairments in pediatric economic evaluations: case studies and a critique

(2010) Scott D Grosse et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A

(2009) A. MINERS   HAEMOPHILIA

Improving Decision Analyses: Parent Preferences (Utility Values) for Pediatric Health Outcomes

(2009) Aaron E. Carroll et al.   JOURNAL OF PEDIATRICS

Comparison of 5 Health-Related Quality-of-Life Indexes Using Item Response Theory Analysis

(2009) Dennis G. Fryback et al.   MEDICAL DECISION MAKING

An assessment of the relative influence of pain coping, negative thoughts about pain, and pain acceptance on health-related quality of life among people with hemophilia

(2009) James Elander et al.   PAIN

Challenges of Patient-Reported Outcome Assessment in Hemophilia Care—a State of the Art Review

(2009) Monika Bullinger et al.   VALUE IN HEALTH

QALYs: Some Challenges

(2009) Erik Nord et al.   VALUE IN HEALTH

Cross-cultural development and psychometric evaluation of a patient-reported health-related quality of life questionnaire for adults with haemophilia

(2008) A. RENTZ et al.   HAEMOPHILIA

Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A

(2008) N. RISEBROUGH et al.   HAEMOPHILIA

Effects of secondary prophylaxis started in adolescent and adult haemophiliacs

(2008) A. TAGLIAFERRI et al.   HAEMOPHILIA

Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors

(2008) W. K. HOOTS et al.   HAEMOPHILIA

Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold

(2008) Scott D Grosse   Expert Review of Pharmacoeconomics & Outcomes Research